Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glecaprevir/pibrentasvir - AbbVie

Next Previous
X
Search
Drug Profile

Glecaprevir/pibrentasvir - AbbVie

Alternative Names: 2DAA; ABT-493/ABT-530; GLE/PIB; Glecaprevir Hydrate/Pibrentasvir - AbbVie; HCV Next Gen; MAVIRET; MAVYRET; Pibrentasvir/glecaprevir; Pibrentasvir/glecaprevir-Abbvie

Latest Information Update: 15 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie; Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Antivirals; Aza compounds; Benzimidazoles; Carbamates; Cyclic ethers; Cyclopentanes; Cyclopropanes; Fluorobenzenes; Piperidines; Pyrrolidines; Quinoxalines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 02 Sep 2024 AbbVie completes a phase III clinical trials in Hepatitis C (In adolescents, In the elderly, In adults) in USA, Canada, France, Germany, Italy, Spain, Australia, Austria (PO) (NCT04903626)
  • 03 Mar 2024 Efficacy and adverse events data from the phase II PURGE-C trial in Hepatitis C presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024 (CROI 2024)
  • 22 Aug 2023 AbbVie in collaboration with National Institute of Allergy and Infectious Diseases (NIAID) completes a phase II PURGE-C trial for Hepatitis C in USA, Puerto Rico and Brazil (NCT04042740)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top